Research programme: Parkinson's disease therapies - Lysosomal Therapeutics

Drug Profile

Research programme: Parkinson's disease therapies - Lysosomal Therapeutics

Alternative Names: LTI-291

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Lysosomal Therapeutics
  • Class Small molecules
  • Mechanism of Action Glucosylceramidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Parkinson's disease

Most Recent Events

  • 09 Jan 2017 Allergan purchases an exclusive option right to acquire Lysosomal Therapeutics
  • 09 Jan 2017 Lysosomal Therapeutics plans a phase 1b trial for Parkinson's Disease
  • 12 May 2014 Early research in Parkinson's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top